The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
Background: Infliximab is an effective therapy for Crohn's disease (CD). Early non-invasive predictors of disease remission allow for modification of treatments. The aim of this study was to investigate the associations between genetic variants, pharmacokinetics, and infliximab efficacy in pedi...
Saved in:
Main Authors: | Wenhui Hu (Author), Yan Feng (Author), Ziqing Ye (Author), Zifei Tang (Author), Lai Qian (Author), Yuhuan Wang (Author), Ying Huang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China
by: Ping Li, et al.
Published: (2024) -
The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients
by: Wenjuan Tang, et al.
Published: (2022) -
Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile
by: Luz María Medrano, et al.
Published: (2015) -
Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn's disease
by: Kouzhu Zhu, et al.
Published: (2023) -
The impact of medication belief on adherence to infliximab in patients with Crohn's disease
by: Shuyan Li, et al.
Published: (2023)